Statistics from Altmetric.com
We read with great interest the articles by Kostine et al 1 (and subsequent correspondence by Arnaud et al 2) and by Belkhir et al. 3 The prognosis of various cancer types has dramatically improved since the advent of immune checkpoint inhibitors (ICIs). Yet, ICI therapy is associated with frequent and potentially organ or life-threatening immune-related adverse events (irAEs), generally mimicking autoimmune or inflammatory conditions.4 Rheumatic disorders have been reported in this setting, mainly rheumatoid arthritis, polymyalgia rheumatica and systemic lupus erythematosus.1–3 Vasculitis seems to occur more seldom, with predominantly medium-vessel to large-vessel involvement.5 Here, we report on a patient with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) following treatment with ICI for a stage IV melanoma.
A 34-year-old non-smoking female patient with stage IV melanoma was treated with ipilimumab (a monoclonal antibody targeting the cytotoxic T–lymphocyte associated antigen …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.